Abbott Laboratories (NYSE: ABT) reported second quarter 2023 earnings results today. Net sales decreased 11.4% year-over-year to $10 billion. Organic sales growth, excluding COVID-19 tests, was 11.5%. GAAP net income decreased 32% to $1.37 billion, or $0.78 per share, from last year. Adjusted EPS fell 24.5% to $1.08. For full-year 2023, adjusted EPS is expected to […]
Abbott Laboratories (NYSE: ABT) reported second quarter 2023 earnings results today. Net sales decreased 11.4% year-over-year to $10 billion. Organic sales growth, excluding COVID-19 tests, was 11.5%. GAAP net income decreased 32% to $1.37 billion, or $0.78 per share, from last year. Adjusted EPS fell 24.5% to $1.08. For full-year 2023, adjusted EPS is expected to […]
Abbott Laboratories (NYSE: ABT) reported second quarter 2023 earnings results today.
Net sales decreased 11.4% year-over-year to $10 billion. Organic sales growth, excluding COVID-19 tests, was 11.5%.
GAAP net income decreased 32% to $1.37 billion, or $0.78 per share, from last year. Adjusted EPS fell 24.5% to $1.08.
For full-year 2023, adjusted EPS is expected to range between $4.30-4.50.
